Could Pfizer Stock Be Your Ticket to Generational Wealth?

Pfizer stock has declined over 50% from its 2021 peak, driving its dividend yield to 6.8%. While the company faces near-term headwinds from patent expirations on key drugs and lacks immediate replacements, analysts suggest long-term investors should view this as a turnaround opportunity. With a century-long track record and several drug trials scheduled for 2026, Pfizer is expected to navigate this difficult period and return to growth, potentially offering both income and capital appreciation.